Your session is about to expire
← Back to Search
Other
Bempedoic acid 180 mg tablet for Cardiovascular Disease (CLEAR Outcomes Trial)
Phase 3
Waitlist Available
Research Sponsored by Esperion Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 68 months
Awards & highlights
CLEAR Outcomes Trial Summary
This trial will test if bempedoic acid can help people who can't tolerate statins by reducing their risk of cardiovascular events.
Eligible Conditions
- Cardiovascular Disease
- Statin Adverse Reaction Syndrome
CLEAR Outcomes Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 68 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 68 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants With First Occurrence of Four Component Major Adverse Cardiovascular Events (MACE)
Secondary outcome measures
Number of Participants With First Occurrence of Myocardial Infarction
Number of Participants With First Occurrence of Three Component MACE
Number of Participants With Time to All-cause Mortality
+3 moreSide effects data
From 2022 Phase 3 trial • 13970 Patients • NCT0299340611%
Hyperuricaemia
11%
Hypertension
10%
COVID-19
8%
Urinary tract infection
8%
Arthralgia
7%
Diabetes mellitus
7%
Headache
6%
Blood uric acid increased
6%
Myalgia
6%
Back pain
5%
Nasopharyngitis
1%
Cholelithiasis
1%
Pneumonia
1%
Angina pectoris
1%
Non-cardiac chest pain
1%
Osteoarthritis
1%
COVID-19 pneumonia
1%
Angina unstable
1%
Transient ischaemic attack
1%
Atrial fibrillation
1%
Cardiac failure congestive
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bempedoic Acid 180 mg
Placebo Comparator
CLEAR Outcomes Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Bempedoic Acid 180 mgExperimental Treatment1 Intervention
Bempedoic acid 180 mg tablet taken orally, once daily.
Group II: Placebo ComparatorPlacebo Group1 Intervention
Matching placebo tablet taken orally, once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bempedoic acid
FDA approved
Find a Location
Who is running the clinical trial?
Esperion Therapeutics, Inc.Lead Sponsor
25 Previous Clinical Trials
7,948 Total Patients Enrolled
The Cleveland ClinicOTHER
1,034 Previous Clinical Trials
1,351,455 Total Patients Enrolled
Michael Louie, MDStudy DirectorEsperion Therapeutics, Inc.
2 Previous Clinical Trials
74 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger